Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500903-38-00

Acronym

38RC22.210 LIVERNET1

Enrollment

Registered

2022-11-15

Start date

2023-02-09

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable hepatocellular carcinoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026